Article

Amgen's First-in-Class Viral Drug, T-Vec, Could Soon Be Approved by EMA

Author(s):

The drug is awaiting an FDA verdict next week.

The European Medicine Agency (EMA) has approved Amgen's tumor-killing virus, talimogene laherparepvec (T-Vec) for treating unresectable melanoma that has not metastasized. Imlygic uses a modified herpes simplex virus that is targeted to infect cancer cells alone. The virus, injected directly into the tumors, replicates and causes the cancer cells to rupture. The resulting immune system response is responsible for the antigenic response against the tumor.

The product is due for an FDA verdict by October 27, 2015.

Read more here: http://reut.rs/1W9QCJA.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr John Mascarenhas
5 experts are featured in this series
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr John Mascarenhas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo